← 產業報告目錄
Hematology Indications Related Drugs Industry Research Report 2026
出版商 APO Research產業別 Healthcare & Life Sciences出版日期 2026-01-02頁數 119報告編號 APO-268adcc422
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global Hematology Indications Related Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Hematology Indications Related Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Hematology Indications Related Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Hematology Indications Related Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Hematology Indications Related Drugs include Alexion Pharmaceuticals, AllCells, LLC, Astex Therapeutics, Bicycle Therapeutics, Gilead, Kiadis Pharma, Novo A/S, Nucentra and Owkin, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hematology Indications Related Drugs market in terms of revenue (US$ million) and, where applicable, service volume (Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Hematology Indications Related Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hematology Indications Related Drugs Market by Company
Alexion Pharmaceuticals
AllCells, LLC
Astex Therapeutics
Bicycle Therapeutics
Gilead
Kiadis Pharma
Novo A/S
Nucentra
Owkin
Rennova Health
Sierra Oncology
Spectrum Pharmaceuticals, Inc.
Amgen
Bayer
Hematology Indications Related Drugs Segment by Type
Demethylating Agents
Thrombin Inhibitors
Antiplatelet Agents
Cyclooxygenase Inhibitors
Hematology Indications Related Drugs Segment by Application
Relieve Hematological Complications
Diease Thearpy
Hematology Indications Related Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hematology Indications Related Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hematology Indications Related Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hematology Indications Related Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Hematology Indications Related Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Hematology Indications Related Drugs by Type
2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
2.2.2 Demethylating Agents
2.2.3 Thrombin Inhibitors
2.2.4 Antiplatelet Agents
2.2.5 Cyclooxygenase Inhibitors
2.3 Hematology Indications Related Drugs by Application
2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.3.2 Relieve Hematological Complications
2.3.3 Diease Thearpy
2.4 Assumptions and Limitations
3 Hematology Indications Related Drugs Breakdown Data by Type
3.1 Global Hematology Indications Related Drugs Historic Market Size by Type (2021-2026)
3.2 Global Hematology Indications Related Drugs Forecasted Market Size by Type (2027-2032)
4 Hematology Indications Related Drugs Breakdown Data by Application
4.1 Global Hematology Indications Related Drugs Historic Market Size by Application (2021-2026)
4.2 Global Hematology Indications Related Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
5.1 Global Hematology Indications Related Drugs Market Perspective (2021-2032)
5.2 Global Hematology Indications Related Drugs Growth Trends by Region
5.2.1 Global Hematology Indications Related Drugs Market Size by Region: 2021 VS 2025 VS 2032
5.2.2 Hematology Indications Related Drugs Historic Market Size by Region (2021-2026)
5.2.3 Hematology Indications Related Drugs Forecasted Market Size by Region (2027-2032)
5.3 Hematology Indications Related Drugs Market Dynamics
5.3.1 Hematology Indications Related Drugs Industry Trends
5.3.2 Hematology Indications Related Drugs Market Drivers
5.3.3 Hematology Indications Related Drugs Market Challenges
5.3.4 Hematology Indications Related Drugs Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Hematology Indications Related Drugs Players by Revenue
6.1.1 Global Top Hematology Indications Related Drugs Players by Revenue (2021-2026)
6.1.2 Global Hematology Indications Related Drugs Revenue Market Share by Players (2021-2026)
6.2 Global Hematology Indications Related Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Hematology Indications Related Drugs Head Office and Area Served
6.4 Global Hematology Indications Related Drugs Players, Product Type & Application
6.5 Global Hematology Indications Related Drugs Manufacturers Established Date
6.6 Global Hematology Indications Related Drugs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Hematology Indications Related Drugs Market Size (2021-2032)
7.2 North America Hematology Indications Related Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
7.3 North America Hematology Indications Related Drugs Market Size by Country (2021-2026)
7.4 North America Hematology Indications Related Drugs Market Size by Country (2027-2032)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Hematology Indications Related Drugs Market Size (2021-2032)
8.2 Europe Hematology Indications Related Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
8.3 Europe Hematology Indications Related Drugs Market Size by Country (2021-2026)
8.4 Europe Hematology Indications Related Drugs Market Size by Country (2027-2032)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Hematology Indications Related Drugs Market Size (2021-2032)
9.2 Asia-Pacific Hematology Indications Related Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
9.3 Asia-Pacific Hematology Indications Related Drugs Market Size by Country (2021-2026)
9.4 Asia-Pacific Hematology Indications Related Drugs Market Size by Country (2027-2032)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Hematology Indications Related Drugs Market Size (2021-2032)
10.2 South America Hematology Indications Related Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
10.3 South America Hematology Indications Related Drugs Market Size by Country (2021-2026)
10.4 South America Hematology Indications Related Drugs Market Size by Country (2027-2032)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Hematology Indications Related Drugs Market Size (2021-2032)
11.2 Middle East & Africa Hematology Indications Related Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
11.3 Middle East & Africa Hematology Indications Related Drugs Market Size by Country (2021-2026)
11.4 Middle East & Africa Hematology Indications Related Drugs Market Size by Country (2027-2032)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Alexion Pharmaceuticals
12.1.1 Alexion Pharmaceuticals Company Information
12.1.2 Alexion Pharmaceuticals Business Overview
12.1.3 Alexion Pharmaceuticals Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.1.4 Alexion Pharmaceuticals Hematology Indications Related Drugs Product Portfolio
12.1.5 Alexion Pharmaceuticals Recent Developments
12.2 AllCells, LLC
12.2.1 AllCells, LLC Company Information
12.2.2 AllCells, LLC Business Overview
12.2.3 AllCells, LLC Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.2.4 AllCells, LLC Hematology Indications Related Drugs Product Portfolio
12.2.5 AllCells, LLC Recent Developments
12.3 Astex Therapeutics
12.3.1 Astex Therapeutics Company Information
12.3.2 Astex Therapeutics Business Overview
12.3.3 Astex Therapeutics Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.3.4 Astex Therapeutics Hematology Indications Related Drugs Product Portfolio
12.3.5 Astex Therapeutics Recent Developments
12.4 Bicycle Therapeutics
12.4.1 Bicycle Therapeutics Company Information
12.4.2 Bicycle Therapeutics Business Overview
12.4.3 Bicycle Therapeutics Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.4.4 Bicycle Therapeutics Hematology Indications Related Drugs Product Portfolio
12.4.5 Bicycle Therapeutics Recent Developments
12.5 Gilead
12.5.1 Gilead Company Information
12.5.2 Gilead Business Overview
12.5.3 Gilead Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.5.4 Gilead Hematology Indications Related Drugs Product Portfolio
12.5.5 Gilead Recent Developments
12.6 Kiadis Pharma
12.6.1 Kiadis Pharma Company Information
12.6.2 Kiadis Pharma Business Overview
12.6.3 Kiadis Pharma Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.6.4 Kiadis Pharma Hematology Indications Related Drugs Product Portfolio
12.6.5 Kiadis Pharma Recent Developments
12.7 Novo A/S
12.7.1 Novo A/S Company Information
12.7.2 Novo A/S Business Overview
12.7.3 Novo A/S Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.7.4 Novo A/S Hematology Indications Related Drugs Product Portfolio
12.7.5 Novo A/S Recent Developments
12.8 Nucentra
12.8.1 Nucentra Company Information
12.8.2 Nucentra Business Overview
12.8.3 Nucentra Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.8.4 Nucentra Hematology Indications Related Drugs Product Portfolio
12.8.5 Nucentra Recent Developments
12.9 Owkin
12.9.1 Owkin Company Information
12.9.2 Owkin Business Overview
12.9.3 Owkin Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.9.4 Owkin Hematology Indications Related Drugs Product Portfolio
12.9.5 Owkin Recent Developments
12.10 Rennova Health
12.10.1 Rennova Health Company Information
12.10.2 Rennova Health Business Overview
12.10.3 Rennova Health Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.10.4 Rennova Health Hematology Indications Related Drugs Product Portfolio
12.10.5 Rennova Health Recent Developments
12.11 Sierra Oncology
12.11.1 Sierra Oncology Company Information
12.11.2 Sierra Oncology Business Overview
12.11.3 Sierra Oncology Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.11.4 Sierra Oncology Hematology Indications Related Drugs Product Portfolio
12.11.5 Sierra Oncology Recent Developments
12.12 Spectrum Pharmaceuticals, Inc.
12.12.1 Spectrum Pharmaceuticals, Inc. Company Information
12.12.2 Spectrum Pharmaceuticals, Inc. Business Overview
12.12.3 Spectrum Pharmaceuticals, Inc. Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.12.4 Spectrum Pharmaceuticals, Inc. Hematology Indications Related Drugs Product Portfolio
12.12.5 Spectrum Pharmaceuticals, Inc. Recent Developments
12.13 Amgen
12.13.1 Amgen Company Information
12.13.2 Amgen Business Overview
12.13.3 Amgen Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.13.4 Amgen Hematology Indications Related Drugs Product Portfolio
12.13.5 Amgen Recent Developments
12.14 Bayer
12.14.1 Bayer Company Information
12.14.2 Bayer Business Overview
12.14.3 Bayer Revenue in Hematology Indications Related Drugs Business (2021-2026)
12.14.4 Bayer Hematology Indications Related Drugs Product Portfolio
12.14.5 Bayer Recent Developments
13 Report Conclusion
14 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Hematology Indications Related Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 6. Global Hematology Indications Related Drugs Revenue Market Share by Type (2021-2026)
Table 7. Global Hematology Indications Related Drugs Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 8. Global Hematology Indications Related Drugs Revenue Market Share by Type (2027-2032)
Table 9. Global Hematology Indications Related Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 10. Global Hematology Indications Related Drugs Revenue Market Share by Application (2021-2026)
Table 11. Global Hematology Indications Related Drugs Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 12. Global Hematology Indications Related Drugs Revenue Market Share by Application (2027-2032)
Table 13. Global Hematology Indications Related Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 14. Global Hematology Indications Related Drugs Market Size by Region (2021-2026) & (US$ Million)
Table 15. Global Hematology Indications Related Drugs Market Share by Region (2021-2026)
Table 16. Global Hematology Indications Related Drugs Forecasted Market Size by Region (2027-2032) & (US$ Million)
Table 17. Global Hematology Indications Related Drugs Market Share by Region (2027-2032)
Table 18. Hematology Indications Related Drugs Industry Trends
Table 19. Hematology Indications Related Drugs Industry Drivers
Table 20. Hematology Indications Related Drugs Industry Opportunities and Challenges
Table 21. Hematology Indications Related Drugs Market Restraints
Table 22. Global Top Hematology Indications Related Drugs Players by Revenue (US$ Million) & (2021-2026)
Table 23. Global Hematology Indications Related Drugs Revenue Market Share by Players (2021-2026)
Table 24. Global Hematology Indications Related Drugs Industry Players Ranking, 2024 VS 2025 VS 2026
Table 25. Global Key Players of Hematology Indications Related Drugs, Headquarters and Area Served
Table 26. Global Hematology Indications Related Drugs Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Hematology Indications Related Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Hematology Indications Related Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 31. North America Hematology Indications Related Drugs Market Size by Country (2021-2026) & (US$ Million)
Table 32. North America Hematology Indications Related Drugs Market Size by Country (2027-2032) & (US$ Million)
Table 33. Europe Hematology Indications Related Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 34. Europe Hematology Indications Related Drugs Market Size by Country (2021-2026) & (US$ Million)
Table 35. Europe Hematology Indications Related Drugs Market Size by Country (2027-2032) & (US$ Million)
Table 36. Asia Pacific Hematology Indications Related Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Asia Pacific Hematology Indications Related Drugs Market Size by Region (2021-2026) & (US$ Million)
Table 38. Asia Pacific Hematology Indications Related Drugs Market Size by Country (2027-2032) & (US$ Million)
Table 39. South America Hematology Indications Related Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 40. South America Hematology Indications Related Drugs Market Size by Country (2021-2026) & (US$ Million)
Table 41. South America Hematology Indications Related Drugs Market Size by Country (2027-2032) & (US$ Million)
Table 42. Middle East & Africa Hematology Indications Related Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 43. Middle East & Africa Hematology Indications Related Drugs Market Size by Country (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Hematology Indications Related Drugs Market Size by Country (2027-2032) & (US$ Million)
Table 45. Alexion Pharmaceuticals Company Information
Table 46. Alexion Pharmaceuticals Business Overview
Table 47. Alexion Pharmaceuticals Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 48. Alexion Pharmaceuticals Hematology Indications Related Drugs Product Portfolio
Table 49. Alexion Pharmaceuticals Recent Developments
Table 50. AllCells, LLC Company Information
Table 51. AllCells, LLC Business Overview
Table 52. AllCells, LLC Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 53. AllCells, LLC Hematology Indications Related Drugs Product Portfolio
Table 54. AllCells, LLC Recent Developments
Table 55. Astex Therapeutics Company Information
Table 56. Astex Therapeutics Business Overview
Table 57. Astex Therapeutics Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 58. Astex Therapeutics Hematology Indications Related Drugs Product Portfolio
Table 59. Astex Therapeutics Recent Developments
Table 60. Bicycle Therapeutics Company Information
Table 61. Bicycle Therapeutics Business Overview
Table 62. Bicycle Therapeutics Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 63. Bicycle Therapeutics Hematology Indications Related Drugs Product Portfolio
Table 64. Bicycle Therapeutics Recent Developments
Table 65. Gilead Company Information
Table 66. Gilead Business Overview
Table 67. Gilead Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 68. Gilead Hematology Indications Related Drugs Product Portfolio
Table 69. Gilead Recent Developments
Table 70. Kiadis Pharma Company Information
Table 71. Kiadis Pharma Business Overview
Table 72. Kiadis Pharma Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 73. Kiadis Pharma Hematology Indications Related Drugs Product Portfolio
Table 74. Kiadis Pharma Recent Developments
Table 75. Novo A/S Company Information
Table 76. Novo A/S Business Overview
Table 77. Novo A/S Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 78. Novo A/S Hematology Indications Related Drugs Product Portfolio
Table 79. Novo A/S Recent Developments
Table 80. Nucentra Company Information
Table 81. Nucentra Business Overview
Table 82. Nucentra Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 83. Nucentra Hematology Indications Related Drugs Product Portfolio
Table 84. Nucentra Recent Developments
Table 85. Owkin Company Information
Table 86. Owkin Business Overview
Table 87. Owkin Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 88. Owkin Hematology Indications Related Drugs Product Portfolio
Table 89. Owkin Recent Developments
Table 90. Rennova Health Company Information
Table 91. Rennova Health Business Overview
Table 92. Rennova Health Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 93. Rennova Health Hematology Indications Related Drugs Product Portfolio
Table 94. Rennova Health Recent Developments
Table 95. Sierra Oncology Company Information
Table 96. Sierra Oncology Business Overview
Table 97. Sierra Oncology Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 98. Sierra Oncology Hematology Indications Related Drugs Product Portfolio
Table 99. Sierra Oncology Recent Developments
Table 100. Spectrum Pharmaceuticals, Inc. Company Information
Table 101. Spectrum Pharmaceuticals, Inc. Business Overview
Table 102. Spectrum Pharmaceuticals, Inc. Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 103. Spectrum Pharmaceuticals, Inc. Hematology Indications Related Drugs Product Portfolio
Table 104. Spectrum Pharmaceuticals, Inc. Recent Developments
Table 105. Amgen Company Information
Table 106. Amgen Business Overview
Table 107. Amgen Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 108. Amgen Hematology Indications Related Drugs Product Portfolio
Table 109. Amgen Recent Developments
Table 110. Bayer Company Information
Table 111. Bayer Business Overview
Table 112. Bayer Revenue in Hematology Indications Related Drugs Business (2021-2026) & (US$ Million)
Table 113. Bayer Hematology Indications Related Drugs Product Portfolio
Table 114. Bayer Recent Developments
Table 115. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Hematology Indications Related Drugs Product Image
Figure 5. Global Hematology Indications Related Drugs Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 6. Global Hematology Indications Related Drugs Market Share by Type: 2025 VS 2032
Figure 7. Demethylating Agents Product
Figure 8. Thrombin Inhibitors Product
Figure 9. Antiplatelet Agents Product
Figure 10. Cyclooxygenase Inhibitors Product
Figure 11. Global Hematology Indications Related Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 12. Global Hematology Indications Related Drugs Market Share by Application: 2025 VS 2032
Figure 13. Relieve Hematological Complications Product
Figure 14. Diease Thearpy Product
Figure 15. Global Hematology Indications Related Drugs Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 16. Global Hematology Indications Related Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032
Figure 17. Global Hematology Indications Related Drugs Market Share by Region: 2025 VS 2032
Figure 18. Global Hematology Indications Related Drugs Market Share by Players in 2025
Figure 19. Global Hematology Indications Related Drugs Manufacturers Established Date
Figure 20. Global Top 5 and 10 Hematology Indications Related Drugs Players Market Share by Revenue in 2025
Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 22. North America Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 23. North America Hematology Indications Related Drugs Market Share by Country (2021-2032)
Figure 24. United States Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 25. Canada Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 26. Mexico Hematology Indications Related Drugs Market Share by Country (2021-2032)
Figure 27. Europe Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 28. Europe Hematology Indications Related Drugs Market Share by Country (2021-2032)
Figure 29. Germany Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 30. France Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 31. U.K. Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 32. Italy Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 33. Spain Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 34. Russia Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 35. Netherlands Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 36. Nordic Countries Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 37. Asia-Pacific Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 38. Asia-Pacific Hematology Indications Related Drugs Market Share by Country (2021-2032)
Figure 39. China Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 40. Japan Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 41. South Korea Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 42. India Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 43. India Hematology Indications Related Drugs Market Share by Country (2021-2032)
Figure 44. Australia Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 45. China Taiwan Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 46. Southeast Asia Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 47. South America Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 48. South America Hematology Indications Related Drugs Market Share by Country (2021-2032)
Figure 49. Brazil Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 50. Argentina Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 51. Chile Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 52. Colombia Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 53. Peru Hematology Indications Related Drugs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 54. Alexion Pharmaceuticals Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 55. AllCells, LLC Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 56. Astex Therapeutics Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 57. Bicycle Therapeutics Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 58. Gilead Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 59. Kiadis Pharma Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 60. Novo A/S Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 61. Nucentra Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 62. Owkin Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 63. Rennova Health Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 64. Sierra Oncology Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 65. Spectrum Pharmaceuticals, Inc. Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 66. Amgen Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
Figure 67. Bayer Revenue Growth Rate in Hematology Indications Related Drugs Business (2021-2026)
提及公司
Alexion PharmaceuticalsAllCells, LLCAstex TherapeuticsBicycle TherapeuticsGileadKiadis PharmaNovo A/SNucentraOwkinRennova HealthSierra OncologySpectrum Pharmaceuticals, Inc.AmgenBayer
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們